Confirm folate deficiency, identify dietary, malabsorptive, medicine-related or increased-demand causes, exclude vitamin B12 deficiency safely and deliver replacement with documented response and prevention of recurrence.
Folate supplies one-carbon units for thymidylate and purine synthesis. When stores fall, rapidly dividing marrow precursors cannot replicate DNA normally, creating nuclear-cytoplasmic asynchrony, ineffective erythropoiesis and intramedullary cell death. The resulting blood film resembles vitamin B12 deficiency: macro-ovalocytes, anisopoikilocytosis and hypersegmented neutrophils. LDH and indirect bilirubin may rise, but the absolute reticulocyte response is inappropriately low. Severe disease can cause leucopenia and thrombocytopenia as well as anaemia.
Because body folate reserves are limited, deficiency can develop within months of inadequate intake or increased demand. History should cover restricted diet, alcohol, food access, frailty, pregnancy, chronic haemolysis, dialysis, coeliac disease, inflammatory bowel disease and bowel surgery. Methotrexate, trimethoprim and selected antiseizure medicines require careful indication-specific review rather than abrupt cessation. Serum folate can change with recent eating and supplementation, so results need the blood count, film, B12 and clinical cause alongside them.
Restricted or poor-quality diets, food insecurity, frailty, alcohol dependence and prolonged cooking of food can reduce folate intake and deplete relatively limited stores.
Coeliac disease, inflammatory small-bowel disease, extensive bowel surgery and severe gastrointestinal illness reduce proximal small-intestinal folate uptake.
Pregnancy, chronic haemolysis, rapid growth, malignancy and recovery from major marrow stress increase nucleotide synthesis and can outstrip folate supply.
Methotrexate, trimethoprim, selected antiseizure medicines, dialysis and other treatment contexts can impair folate metabolism, absorption or retention.
Sustained inadequate delivery or increased use exhausts hepatic folate stores over months, faster than the usual time course of vitamin B12 depletion.
Reduced tetrahydrofolate-dependent one-carbon transfer impairs DNA replication, particularly in rapidly dividing marrow and gastrointestinal epithelial cells.
Nuclear development lags behind cytoplasmic growth, creating megaloblasts, macro-ovalocytes, hypersegmented neutrophils and ineffective intramedullary erythropoiesis within marrow.
Precursor cell death lowers reticulocyte output and may reduce several lineages, while falling haemoglobin causes fatigue, breathlessness and cardiovascular compensation.
Macro-ovalocytes, hypersegmented neutrophils, low reticulocytes and possible pancytopenia support folate or B12-related ineffective erythropoiesis rather than simple regeneration.
Restricted food intake, alcohol dependence, frailty, food insecurity or a diet lacking fortified grains and green vegetables increases deficiency likelihood.
Chronic diarrhoea, weight loss, coeliac disease, inflammatory bowel disease or extensive small-bowel surgery suggests impaired folate uptake and possible mixed deficiency.
Pregnancy, chronic haemolysis, rapid growth or active malignancy can outstrip intake and may require a longer cause-specific prevention plan.
Paraesthesia, proprioceptive loss, gait disturbance, cognitive change, gastric surgery or autoimmune history makes folate-only treatment unsafe and B12 assessment urgent.
An identical megaloblastic blood pattern plus neurological disease, malabsorption risks or indeterminate cobalamin testing demands prompt B12 assessment and replacement.
Exposure history, round rather than oval macrocytes, target cells and abnormal liver tests support non-megaloblastic macrocytosis, although nutritional deficiency can coexist.
Persistent macrocytosis, dysplastic neutrophils or platelets, additional cytopenias and failure to respond to adequate haematinic replacement raises clonal marrow disease.
Recent bleeding, haemolysis or recovery after treatment increases larger young red cells; a raised absolute reticulocyte count distinguishes regeneration from ineffective megaloblastosis.
Thyroid failure, hydroxycarbamide, antiretroviral treatment and other medicines produce macrocytosis without folate depletion and require cause-specific interpretation.
Progressive ineffective erythropoiesis reduces oxygen carriage, causing fatigue, exertional breathlessness, palpitations and decompensation in people with limited cardiorespiratory reserve.
Severe megaloblastosis can reduce white cells and platelets as well as red cells, increasing infection or bleeding risk and mimicking marrow failure.
Insufficient folate around conception increases fetal neural-tube-defect risk, while maternal deficiency can contribute to anaemia and adverse pregnancy outcomes.
Folic acid may correct megaloblastic haematology while untreated B12-related neurological injury continues, delaying recognition until disability is established.
Replacement without correcting poor intake, malabsorption, increased demand or medicine interactions leads to renewed depletion after the treatment course ends.
Deficiency can emerge over months, so a recent dietary, alcohol, gastrointestinal or medicine change may be directly relevant.
Macro-ovalocytes and hypersegmented neutrophils occur in both folate and B12 deficiency. Neurology, biochemical testing and cause assessment provide the distinction.
Intramedullary death of megaloblasts releases LDH and bilirubin despite low reticulocytes, creating a misleading resemblance to peripheral haemolysis.
Concurrent iron restriction produces smaller cells and may balance folate-related macrocytosis. RDW and film reveal the mixed population.
Four months of folic acid corrects stores only if poor intake, malabsorption, medicine antagonism or increased demand is also addressed.
Giving folic acid before assessing B12 and neurological symptoms.
Diagnosing folate deficiency from macrocytosis without a folate result and cause assessment.
Ignoring mixed iron deficiency because the MCV is normal.
Stopping methotrexate or antiseizure treatment without specialist coordination.
Extending folic acid indefinitely without explaining continued demand or malabsorption.
Assuming a normalised FBC proves the underlying cause has resolved.
Missing marrow disease when cytopenias fail to respond to adequate replacement.
Your practice draft is saved in this browser.
A patient has macrocytic anaemia, low folate, numb feet and impaired vibration sense. Vitamin B12 testing is still pending. What is the safest immediate approach?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Exclude or treat vitamin B12 deficiency first because folate can improve the blood count while neurological injury progresses. Review methotrexate, trimethoprim and antiseizure interactions with the responsible clinician.
Do not escalate solely for a slow FBC without revisiting adherence, diagnosis, B12 and iron status, continued demand and intestinal disease. Long-term high dosing needs a clear indication.